Pharmaxis (ASX: PXS) is pleased to announce that its Phase III, DPM-B-305 study of inhaled Bronchitol, for the treatment of people with bronchiectasis, has reached its pre-specified recruitment target.

This major Phase III clinical trial received input from both the U.S. and the EU regulators on its design.  The trial will show if treatment with Bronchitol over twelve months leads to a reduction in pulmonary infectious episodes for people with bronchiectasis.  In addition, the trial will collect data on quality of life, lung function and other aspects of the condition.

Read Media Release